Oncogene products represent potential targets of tumor vaccines

Cancer Immunology Immunotherapy

Volumn 43, Issue 3, 1996, Pages 135-141

  Tuttle, T M ^a  

^a PARK NICOLLET CLINIC   (United States)

Author keywords

oncogene products; tumor vaccines

Indexed keywords

CANCER VACCINE; PROTEIN P53;

CANCER IMMUNOTHERAPY; CHROMOSOME TRANSLOCATION; CONFERENCE PAPER; CYTOTOXIC T LYMPHOCYTE; GENE AMPLIFICATION; HUMAN; MAJOR HISTOCOMPATIBILITY COMPLEX; MOUSE; MUTATION; NONHUMAN; ONCOGENE; PRIORITY JOURNAL; T LYMPHOCYTE;

ANIMALS; CYCLIN-DEPENDENT KINASE INHIBITOR P21; CYCLINS; FUSION PROTEINS, BCR-ABL; GENE AMPLIFICATION; GENES, RAS; HUMANS; IMMUNOTHERAPY; MICE; NEOPLASM PROTEINS; NEOPLASMS; RECEPTOR, ERBB-2; T-LYMPHOCYTES, CYTOTOXIC; TUMOR SUPPRESSOR PROTEIN P53;

EID: 0029944924     PISSN: 03407004     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002620050314     Document Type: Conference Paper

References (62)

1. Almoguera C, Shibata D, Forrester K, Martin J, Arnheim N, Peruch M (1988) Most human carcinomas of the exocrine pancreas contain mutant c-K-ras genes. Cell 53: 549
2. Barbacid M (1987) ras genes. Annu Rev Biochem 56: 779
3. Bargmann C, Hung M, Weinberg R (1986) The neu oncogene encodes an epidermal growth factor receptor-related protein. Nature 319: 22
4. Bernards R, Destree A, McKenzie S, Gordon E, Weinberg RA (1987) Effective tumor immunotherapy directed against an oncogene-encoded product using a vaccinia virus vector. Proc Natl Acad Sci USA 84: 6854
5. Bos J (1989) ras oncogenes in human cancer: a review. Cancer Res 49: 4682
6. Bos J, Fearon E, Hamilton S, Vries M, Boom J, Eb A, Vogelstein B (1987) Prevalence of ras gene mutations in human colorectal cancers. Nature 327: 293
7. Caron de Fromentel C, Soussi T (1992) p53 tumor suppressor gene: a model for investigating human mutagenesis. Genes Chromosomes Cancer 4: 1
8. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahasi M, Chen W (1995) Immunity to oncogenic proteins. Immunol Rev 145: 33
9. Chen W, Peace DJ, Rovira DK, You SG, Cheever MA (1992) T-cell immunity to the joining region of p210BCR-ABL protein. Proc Natl Acad Sci USA 89: 1468
10. Chen W, You SG, Disis ML, Cheever MA (1993) Evaluation of the joining region segment of p210BCR-AB1 chimeric protein as a potential leukemia-specific antigen to elicit class I MHC-restricted CTL responses. J Cell Biochem Suppl 17D: 107
11. Coussens L, Yang-Feng TL, Chen YLE, Gray A, McGrath J, Seeburg PH, Liberman TA, Schlessinger J, Francke U, Levinson A, Ullrich A (1985) Tyrosine kinase receptor with extensive homology to EGF receptor shares chromosomal location with neu oncogene. Science 230: 1132
12. Cox AL, Skipper J, Chen Y, Henderson RA, Darrow TL, Shabanowitz J, Engelhard VH, Hunt DF, Slingluff CL (1994) Identification of a peptide recognized by five melanoma-specific human cytotoxic T cell lines. Science 264: 716
13. DeLisi C, Berzofsky JA (1985) T cell antigenic sites tend to be amphipathic structures. Proc Natl Acad Sci USA 82: 7048
14. Der CJ, Finkel T, Cooper GM (1986) Biological and biochemical properties of human rasH genes mutated at codon 61. Cell 44: 167
15. Disis ML, Smith JW, Murphy AE, Chen W, Cheever MA (1994) In vitro generation of human cytotoxic T cells specific for peptides derived from the HER-2/neu proto-oncogene protein. Cancer Res 54: 107
16. Disis ML, Calenoff E, McLaughlin G, Murphy AE, Chen W, Groner B, Jeschke M, Lydon N, McGlynn E, Livingston RB, Moe R, Cheever MA (1994) Existent T-cell and antibody immunity to HER-2/neu protein in patients with breast cancer. Cancer Res 54: 16
17. Falk K, Rotzschke O, Deres K, Metzger J, Jung G, Rammensee HG (1991) Identification of naturally processed viral nonapeptides allows their quantification in infected cells and suggested an allele-specific T cell epitope forecast. J Exp Med 174: 425
18. Fenton RG, Taub DD, Kwak LW, Smith MR, Longo DL (1993) Cytotoxic T-cell response and in vivo protection against tumor cells harboring activated ras proto-oncogenes. J Natl Cancer Inst 85: 1294
19. Fisk B, Blevins TL, Wharton JT, Ioannides CG (1995) Identification of an immunodominant peptide of HER-2/neu protooncogene recognized by ovarian tumor-specific cytotoxic T lymphocyte lines. J Exp Med 181: 2109
20. + T cells recognize a peptide corresponding to a common mutation (13 Gly→Asp). Int J Cancer 56: 40
21. Gale RP, Canaani E (1984) An 8-kilobase abl RNA transcript in chronic myelogenous leukemia. Proc Natl Acad Sci USA 81: 5646
22. Gambacorti-Passerini C, Grignani F, Arienti F, Pandolfi PP, Pelicii PG, Parmiani G (1993) Human CD4 lymphocytes specifically recognize a peptide representing the fusion region of the hybrid protein pml/RAR-alpha present in acute promyelocytic leukemia cells. Blood 81: 1369
23. Gedde-Dahl T, Eriksen JA, Thorsby E, Gaudernack G (1992) T-cell responses against products of oncogenes: generation and characterization of human T-cell clones specific for p21 ras-derived synthetic peptides. Hum Immunol 33: 266
24. Gedde-Dahl T, Purkland A, Eriksen JA, Thorsby E, Gaudenack G (1992) Memory T cells of a patient with follicular thyroid carcinoma recognize peptides derived from mutated p21 ras (Gln→Leu61) Int Immunol 4: 1331
25. Gjersen MK, Bakka A, Breivik J, Saeterdal I, Solheim BG, Soreide O, Thornsby E, Gaudernack G (1995) Vaccination with mutant ras peptides and induction of T-cell responsiveness in pancreatic carcinoma patients carrying the corresponding ras mutation. Lancet 346: 1399
26. Gnjatic S, Paillerets B de, Guillet J, Choppin J (1995) Mapping and ranking of potential cytotoxic T epitopes in the p53 protein: effect of mutations and polymorphism on peptide binding to purified and refolded HLA molecules. Eur J Immunol 25: 1638
27. Hollstein M, Sidransky D, Vogelstein B, Harris CC (1991) p53 mutations in human cancers. Science 253: 49
28. Houbiers JGA, Nijman HW, Burg SH van der, Drijfhout JW, Kenemans P, Velder CJH an de, Brand A, Momburg F, Kast WM, Melief CJM (1993) In vitro induction of human cytotoxic T lymphocytes responses against peptides of mutant and wild-type p53. Eur J Immunol 23: 2072
29. Ioannides CG, Ioannides MG, O'Brian CA (1992) T cell recognition of oncogene products: a new strategy tor immunotherapy. Mol Carcinog 6: 77
30. Jung S, Schluesener HJ (1991) Human T lymphocytes recognize a peptide of single point-mutated, oncogenic ras proteins. J Exp Med 173: 273
31. Kawakami Y, Eliyahu S, Delgoda CH, Robbins PF, Sakaguchi K, Appella E, Yannelli JR, Adema GJ, Miki T, Rosenberg SA (1994) Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 91: 6458
32. Kawakami Y, Eliyahu S, Jennings C, Sakaguchi K, Kang X, Southwood S, Robbins PF, Sette A, Appella E, Rosenberg SA (1995) Recognition of multiple epitopes in the human melanoma antigen gp100 by tumor-infiltrating T lymphocytes associated with in vivo tumor regression. J Immunol 154: 3961
33. Konopka JB, Watanabe SM, Witte ON (1984) An alteration of the human c-abl protein in K562 leukemia cells unmasks associated tyrosine kinase activity. Cell 37: 1035
34. Levine AJ, Momand J, Finlay CA (1991) The p53 tumour suppressor gene. Nature 351: 453
35. Levine AJ (1993) The tumor suppressor genes. Annu Rev Biochem 62: 636
36. Lubin R, Schlichtholz B, Bengoufa D, Azlcman G, Tredaniel J, Hirsch A, de Fromentel CC, Preudhomme C, Fenauz P, Fournier G, Mangin P, Laurent-Puig P, Pelletier G, Schlumberger M, Desgrandchamps F, Le Duc A, Peyrat JP, Janin N, Bressac B, Soussi T (1993) Analysis of p53 antibodies in patients with various cancers define B-cell epitopes of human p53: distribution on primary structure and exposure on protein surface. Cancer Res 53: 5872
37. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J, Gryka MA, Bischoff FZ, Tainsky MA, Friend SH (1990) Germ line p53 mutations in a familial syndrome of breast cancer, sarcomas and other neoplasms. Science 250: 1233
38. Margalit H, Spouge JL, Cornette JL, Cease KB, DeLisi C, Berzofsky JA (1987) Prediction of immunodominant helper T cell antigenic sites from the primary sequence. J Immunol 138: 2213
39. + T cells. Proc Natl Acad Sci USA 91: 3171
40. Noguchi Y, Richards EC, Chen Y, Old LJ (1995) Influence of interleukin 12 on p53 peptide vaccination against established Meth A sarcoma. Proc Natl Acad Sci USA 92: 2219
41. Melief CJM, Kast WM (1993) Potential immunogenicity of oncogene and tumor suppressor gene products. Curr Opin Immunol 5: 709
42. Peace DJ, Chen W, Nelson H, Cheever MA (1991) T cell recognition of transforming proteins encoded by mutated ras proto-oncogenes. J Immunol 146: 2059
43. Peace DJ, Smith JW, Disis ML, Chen W, Cheever MA (1993) Induction of T cells specific for the mutated segment of oncogenic p21 ras protein by immunization in vivo with the oncogenic protein. J Immunother 14: 110
44. Peace DJ, Smith JW, Chen W, Sheng-Guo Y, Cosand WL, Blake J, Cheever MA (1994) Lysis of ras oncogene-transformed cells by specific cytotoxic T lymphocytes elicited by primary in vitro immunization with mutated ras peptide. J Exp Med 179: 473
45. Peoples GE, Smith RC, Linehan DC, Yoshino I, Goedegebuure PS, Eberlein TJ (1995) Shared T cell epitopes in epithelial tumors. Cell Immunol 164: 279
46. Peoples GE, Goedegebuure PS, Smith RC, Linehan DC, Yoshino I, Eberlein TJ (1995) Breast and ovarian cancer-specific cytotoxic T lymphocytes recognize the same HER2/neu-derived peptide. Proc Natl Acad Sci USA 92: 432
47. + T-cell immunity to mutated ras protein in pancreatic and colon cancer patients. Can Res 55: 2984
48. Rilke F, Colnaghi MI, Cascinelli N, Andreola S, Baldini MT, Bufalino R, Della Porta G, Manard S, Pierotti MA, Testori A (1991) Prognostic significance of HER-2/neu expression in breast cancer and its relationship to other prognostic factors. Int J Cancer 49: 44
49. Ropke M, Regner M, Claesson MH (1995) T cell-mediated cytotoxicity against p53-protein derived peptides in bulk and limiting dilution cultures of healthy donors. Scand J Immunol 42: 98
50. Rothbard JB, Tayor WR (1988) A sequence pattern common to T cell epitopes. EMBO J 7: 93
51. Rudensky AY, Preston-Hurlburt P, Hong SC, Barlow A, Jane-way J (1991) Sequence analysis of peptides bound to MHC class II molecules. Nature 353: 622
52. Sadegh-Nasseri S, Germain RN (1991) A role for peptide in determining MHC class II structure. Nature 353: 167
53. Schlichtholz B, Legros Y, Gillet D, Gaillard C, Marty M, Lane D, Calvo F, Soussi T (1992) The immune response to p53 in breast cancer patients is directed against immunodominant epitopes unrelated to the mutational hot spot. Cancer Res 52: 6380
54. Seeburg PH, Colby WW, Capon DJ, Goeddel DV, Levinson AD (1984) Biological properties of human c-Ha-ras 1 genes mutated at codon 12. Nature 312: 71
55. Shtivelman E, Lifshitz B, Gale RP, Canaani E (1985) Fused transcript of abl and her genes in chronic myelogenous leukaemia. Nature 315: 550
56. Skipper J, Stauss HJ (1993) Identification of two cytotoxic T lymphocyte-recognized epitopes in the ras protein. J Exp Med 177: 1493
57. Slamon DJ, Godolphin W, Jones LA, Holt JA, Wong SG, Keith DE, Levin WJ, Stuart SG, Udove J, Ullrich A, Press MF (1989) Studies of the HER-2/neu protooncogene in human breast and ovarian cancer. Science 244: 707
58. Srivastava S, Zou ZQ, Pirollo K, Blattner W, Chang EH (1990) Germline transmission of a mutated p53 gene in a cancer-prone family with Li-Fraumeni syndrome. Nature 348: 747
59. Tilkin AF, Lubin R, Soussi T, Lazar V, Janin N, Mathieu MC, Lefrere I, Carlu C, Roy M, Kayibanda M, Bellet D, Guillet JG, Bressac-dePaillerets B (1995) Primary proliferative T cell response to wild-type p53 protein in patients with breast cancer. Eur J Immunol 25: 1765
60. Van-Bleek GM, Nathenson SG (1990) Isolation of an endogenously processed immunodominant viral peptide from the class I H-2Kb molecule. Nature 348: 213
61. Vogelstein B, Fearon ER, Hamilton SR, Kern SE, Preisinger AC, Leppert M, Nakamura Y, White R, Smits AMM, Bos JL (1988) Genetic alterations during colorectal tumor-development. N Engl J Med 319: 525
62. + cytotoxic T-cells. Cancer Res 53: 3257